Merck Still a “Buy” at UBS after New Osteoporosis Drug Proves Useful in Clinical Trial (MRK)

By
A A A
Share |

Pharmaceuticals maker Merck & Co., Inc. ( MRK ) on Friday received some bullish commentary from analysts at UBS.

The firm maintained its "Buy" rating and $45 price target on MRK, suggesting just a 5% upside to the stock's Thursday closing price of $42.91. UBS noted that the company's new osteoporosis drug, dubbed Odanacatib, has shown promise in recently trials.

Merck shares, which have risen nearly 14% year-to-date, were mostly flat in premarket trading Friday.

The Bottom Line
Shares of Merck ( MRK ) have a 3.92% dividend yield, based on last night's closing stock price of $42.91. The stock has technical support in the $38-$39 price area. If the shares can firm up, we see overhead resistance around the $45-$47 price levels.

Merck & Co., Inc. ( MRK ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com


This article appears in: Investing , Stocks

Referenced Stocks: MRK

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

86,627,350
  • $61.80 ▼ 3.33%
58,636,005
  • $15.44 ▼ 1.03%
43,254,709
  • $64.8725 ▼ 0.15%
39,355,269
  • $3.38 ▲ 0.90%
39,064,711
  • $4.29 ▲ 1.42%
38,037,134
  • $95.035 ▼ 0.37%
36,100,193
  • $94.66 ▼ 0.32%
32,857,379
  • $26.20 ▼ 0.46%
As of 7/10/2014, 04:04 PM